CG Oncology CGON Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Profitability | |||
| Operating margin | -4,722.1%+5,345pp | -10,067.3%+17,112pp | |
| Net margin | -3,985%+3,744pp | -7,729.5%+16,097pp | |
| EBITDA margin | -4,686.4%+5,378pp | -10,064.4%+17,106pp | |
| Free cash flow margin | -3,279.2%+3,652pp | -6,931.3%— | |
| Returns | |||
| Return on equity | -21.7%— | —— | |
| Return on assets | -20.8%-2.4pp | -18.5%— | |
| Return on invested capital | -31.7%— | —— | |
| Efficiency | |||
| Asset turnover | 0×0.0× | 0×— | |
| Liquidity | |||
| Current ratio | 24.6×-10.7× | 35.3×+21.7× | |
| Quick ratio | 24.6×-10.7× | 35.3×+21.7× | |
| Cash ratio | 1.1×-11.0× | 12×+11.5× | |
| Leverage | |||
| Debt-to-equity | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | |
| Per Share | |||
| Book value per share | $9.74-17.0% | $11.73+141% | |
| Valuation | |||
| Market capitalization | $3.35B+53.4% | $2.18B— | |
| Enterprise value | $3.32B+72.5% | $1.93B— | |
| Price / sales | 829×-1,088× | 1,916.9×— | |
| Price / book | 4.5×+1.5× | 3×— | |
| EV / sales | 822.7×-869× | 1,691.5×— | |
| Free cash flow yield | -4%-0.3pp | -3.6%— | |
| Earnings yield | -4.8%-0.8pp | -4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CG Oncology's ratios come from?
- Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.